<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Alzheimers.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:30:05 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=ISO-8859-1">
<meta name="Language" content="es">
<meta name="ContentID" content="1007001">
<meta name="Category" content="Concern">
<meta name="Article" content="Alzheimers">
<title>Enfermedad de Alzheimer-Referencias</title>
<link type="text/css" rel="stylesheet" href="../Styles/hnqrHtml.css">
<base target="_self">
</head>
<body>
<div id="Article-Title" class="Article-Title"><a name="Article-Title"></a> 

<p class="Article-Title">Enfermedad de Alzheimer</p>
</div>

<div id="Reference-List" class="Reference-List">
<p class="Reference-Autofill"><a href="Alzheimers.htm">Volver al
art&#237;culo.</a></p>

<h3>Referencias para el art&#237;culo</h3>

<ol class="Reference-List">
<li class="Ref">Priest ND. Satellite symposium on Alzheimer&#8217;s disease and dietary
aluminum. <em>Proc Nutr Soc</em> 1993;52:231&#8211;40.</li>

<li class="Ref">Munoz DG. Is exposure to aluminum a risk factor for the development of
Alzheimer disease?&#8212;No. <em>Arch Neurol</em> 1998;737&#8211;9 [review].</li>

<li class="Ref">Munoz DG. Is exposure to aluminum a risk factor for the development of
Alzheimer disease?&#8212;No. <em>Arch Neurol</em> 1998;55:737&#8211;9.</li>

<li class="Ref">Forbes WF, Hill GB. Is exposure to aluminum a risk factor for the development
of Alzheimer disease?&#8212;Yes. <em>Arch Neurol</em> 1998;55:740&#8211;1.</li>

<li class="Ref">Rogers MA, Simon DG. A preliminary study of dietary aluminium intake and risk
of Alzheimer&#8217;s disease. <em>Age Ageing</em> 1999;28:205&#8211;9.</li>

<li class="Ref">Grant WB. Dietary links to Alzheimer&#8217;s disease. <em>Alzheimer Dis
Rev</em> 1997;2:42&#8211;55.</li>

<li class="Ref">Smith MA, Petot GJ, Perry G. Diet and oxidative stress: a novel synthesis of
epidemiological data on Alzheimer&#8217;s disease. <em>Alzheimer Dis Rev</em>
1997;2:58&#8211;9.</li>

<li class="Ref">Kalmijn S, Lauher LJ, Ott A, et al. Dietary fat intake and the risk of
incident dementia in the Rotterdam study. <em>Ann Neurol</em> 1997;42:776&#8211;82.</li>

<li class="Ref">Friedland R. American Academy of Neurology&#8217;s 52nd Annual Meeting in San
Diego, CA, April 29&#8211;May 6, 2000.</li>

<li class="Ref">Pettegrew JW, Klunk WE, Panchalingam K, et al. Clinical and neurochemical
effects of acetyl-L-carnitine in Alzheimer&#8217;s disease. <em>Neurobiol Aging</em>
1995;16:1&#8211;4.</li>

<li class="Ref">Salvioli G, Neri M. L-acetylcarnitine treatment of mental decline in the
elderly. <em>Drugs Exp Clin Res</em> 1994;20:169&#8211;76.</li>

<li class="Ref">Rai G, Wright G, Scott L, et al. Double-blind, placebo controlled study of
acetyl-l-carnitine in patients with Alzheimer&#8217;s dementia. <em>Curr Med Res Opin</em>
1990;11:638&#8211;47.</li>

<li class="Ref">Sano M, Bell K, Cote L, et al. Double-blind parallel design pilot study of
acetyl levocarnitine in patients with Alzheimer&#8217;s disease. <em>Arch Neurol</em>
1992;49:1137&#8211;41.</li>

<li class="Ref">Cucinotta D et al. Multicenter clinical placebo-controlled study with
acetyl-L-carnitine (LAC) in the treatment of mildly demented elderly patients. <em>Drug
Development Res</em> 1988;14:213&#8211;6.</li>

<li class="Ref">Bonavita E. Study of the efficacy and tolerability of L-acetylcarnitine
therapy in the senile brain. <em>Int J Clin Pharmacol Ther Toxicol</em>
1986;24:511&#8211;6.</li>

<li class="Ref">Thal LJ, Carta A, Clarke WR, et al. A 1-year multi-center placebo-controlled
study of aceyl-L-carnitine in patients with Alzheimer&#8217;s disease. <em>Neurology</em>
1996;47:705&#8211;11.</li>

<li class="Ref">Calvani M, Carta A, Caruso G, et al. Action of acetyl-L-carnitine in
neurodegeneration and Alzheimer&#8217;s disease. <em>Ann NY Acad Sci</em>
1992;663:483&#8211;6.</li>

<li class="Ref">Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitamin C supplement
use and risk of incident Alzheimer disease. <em>Alzheimer Dis Assoc Disord</em>
1998;12:121&#8211;6.</li>

<li class="Ref">Schmidt R, Hayn M, Reinhart B, et al. Plasma antioxidants and cognitive
performance in middle-aged and older adults: results of the Austrian Stroke Prevention Study.
<em>J Am Geriatr Soc</em> 1998;46:1407&#8211;10.</li>

<li class="Ref">Lethem R, Orrell M. Antioxidants and dementia. <em>Lancet</em>
1997;349:1189&#8211;90 [commentary].</li>

<li class="Ref">Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline,
alpha-tocopherol, or both as treatment for Alzheimer&#8217;s disease. <em>N Engl J Med</em>
1997;336:1216&#8211;22.</li>

<li class="Ref">Eder L, Hirt L, Dunant Y. Possible involvement of thiamine in acetylcholine
release. <em>Nature</em> 1976;264:186&#8211;8.</li>

<li class="Ref">Eder L, Dunant Y, Loctin F. Thiamine and cholinergic transmission in the
electric organ of Torpedo. <em>J Neurochem</em> 1980;35:1278&#8211;96.</li>

<li class="Ref">Gibson GE, Sheu KF, Blass JP, et al. Reduced activities of thiamine-dependent
enzymes in the brains and peripheral tissues of patients with Alzheimer&#8217;s disease. <em>
Arch Neurol</em> 1988;45:836&#8211;40.</li>

<li class="Ref">Meador K, Loring D, Nichols M, et al. Preliminary findings of high-dose
thiamine in dementia of Alzheimer&#8217;s type. <em>J Geriatr Psychiatry Neurol</em>
1993;6:222&#8211;9.</li>

<li class="Ref">Blass JP, Gleason P, Brush D, et al. Thiamine and Alzheimer&#8217;s disease. A
pilot study. <em>Arch Neurol</em> 1988;45:833&#8211;5.</li>

<li class="Ref">Nolan KA, Black RS, Sheu KF, et al. A trial of thiamine in Alzheimer&#8217;s
disease. <em>Arch Neurol</em> 1991;48:81&#8211;3.</li>

<li class="Ref">Crook T, Petrie W, Wells C, Massari DC. Effects of phosphatidylserine in
Alzheimer&#8217;s disease. <em>Psychopharmacol Bull</em> 1992;28:61&#8211;6.</li>

<li class="Ref">Amaducci L. Phosphatidylserine in the treatment of Alzheimer&#8217;s disease:
results of a multicenter study. <em>Psychopharmacol Bull</em> 1988;24:130&#8211;4.</li>

<li class="Ref">Engel RR, Satzger W, Gunther W, et al. Double-blind cross-over study of
phosphatidylserine vs. placebo in patients with early dementia of the Alzheimer type. <em>Eur
Neuropsychopharmacol</em> 1992;2:149&#8211;55.</li>

<li class="Ref">Heiss WD, Kessler J, Mielke R, et al. Long-term effects of phosphatidylserine,
pyritinol, and cognitive training in Alzheimer&#8217;s disease. A neuropsychological, EEG, and
PET investigation. <em>Dementia</em> 1994;5:88&#8211;98.</li>

<li class="Ref">Gindin J, Novickov M, Kedar D, et al. The effect of plant phosphatidylserine
on age-associated memory impairment and mood in the functioning elderly. Rehovot, Israel:
Geriatric Institute for Education and Research, and Department of Geriatrics, Kaplan Hospital,
1995.</li>

<li class="Ref">Little A, Levy R, Chuaqui-Kidd P, Hand D. A double-blind, placebo controlled
trial of high-dose lecithin in Alzheimer&#8217;s disease. <em>J Neurol Neurosurg
Psychiatry</em> 1985;48:736&#8211;42.</li>

<li class="Ref">Gauthier S, Bouchard R, Lamontagne A, et al. Tetrahydroaminoacridine-lecithin
combination treatment in patients with intermediate-stage Alzheimer&#8217;s disease. Results
of a Canadian double-blind, crossover, multicenter study. <em>N Engl J Med</em>
1990;322:1272&#8211;6.</li>

<li class="Ref">Chatellier G, Lacomblez L. Tacrine (tetrahydroaminoacridine; THA) and lecithin
in senile dementia of the Alzheimer type: a multicentre trial. Groupe Francais d&#8217;Etude
de la Tetrahydroaminoacridine. <em>BMJ</em> 1990;300:495&#8211;9.</li>

<li class="Ref">Fitten LJ, Perryman KM, Gross PL, et al. Treatment of Alzheimer&#8217;s
disease with short- and long-term oral THA and lecithin: a double-blind study. <em>Am J
Psychiatry</em> 1990;147:239&#8211;42.</li>

<li class="Ref">Eagger SA, Levy R, Sahakian BJ. Tacrine in Alzheimer&#8217;s disease. <em>
Lancet</em> 1991;338:50&#8211;1 [letter; comment].</li>

<li class="Ref">Ferris SH, Sathananthan G, Gershon S, et al. Senile dementia. Treatment with
Deanol. <em>J Am Geriatr Soc</em> 1977;25:241&#8211;4.</li>

<li class="Ref">Fisman M, Mersky H, Helmes E. Double-blind trial of 2-dimethylaminoethanol in
Alzheimer&#8217;s disease. <em>Am J Psychiatry</em> 1981;138:970&#8211;2.</li>

<li class="Ref">Imagawa M, Naruse S, Tsuji S, et al. Coenzyme Q10, iron, and vitamin B6 in
genetically-confirmed Alzheimer&#8217;s disease. <em>Lancet</em> 1992;340:671 [letter].</li>

<li class="Ref">Bush AI, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A8
amyloid formation by zinc. <em>Science</em> 1994;265:1464&#8211;5.</li>

<li class="Ref">Potocnik FCV, van Rensburg SJ, Park C, et al. Zinc and platelet membrane
microviscosity in Alzheimer&#8217;s disease. The in vivo effect of zinc on platelet membranes
and cognition<em>. S Afr Med J</em> 1997;87:1116&#8211;9.</li>

<li class="Ref">Prasad AS. Zinc in human health: an update. <em>J Trace Elem Exp Med</em>
1998;11:63&#8211;87.</li>

<li class="Ref">Birkmayer JGD. Coenzyme nicotinamide adenine dinucleotide: New therapeutic
approach for improving dementia of the Alzheimer type. <em>Ann Clin Lab Sci</em>
1996;26:1&#8211;9.</li>

<li class="Ref">Clarke R, Smith D, Jobst KA, et al. Folate, vitamin B12, and serum total
homocysteine levels in confirmed Alzheimer disease. <em>Arch Neurol</em>
1998;55:1449&#8211;55.</li>

<li class="Ref">Snowdon DA, Tully CL, Smith CD, et al. Serum folate and the severity of
atrophy of the neocortex in Alzheimer disease: findings from the Nun study. <em>Am J Clin
Nutr</em> 2000;71:993&#8211;8.</li>

<li class="Ref">Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin
B-12 and folate deficiency more frequent in elderly patients with Alzheimer&#8217;s disease?
<em>J Gastroenterol</em> 1997;52A:M76&#8211;M79.</li>

<li class="Ref">Ebly EM, Schaefer JP, Campbell NR, Hogan DB. Folate status, vascular disease
and cognition in elderly Canadians. <em>Age Ageing</em> 1998;27:485&#8211;91.</li>

<li class="Ref">Hillen T, Lun A, Reischies FM, et al. DHEA-S plasma levels and incidence of
Alzheimer&#8217;s disease. <em>Biol Psychiatry</em> 2000;47:161&#8211;3.</li>

<li class="Ref">Nasman B, Olsson T, Backstrom T, et al. Serum dehydroepiandrosterone sulfate
in Alzheimer&#8217;s disease and in multi-infarct dementia. <em>Biol Psychiatry</em>
1991;30:684&#8211;90.</li>

<li class="Ref">Sunderland T, Merril CR, Harrington MG, et al. Reduced plasma
dehydroepiandrosterone concentrations in Alzheimer&#8217;s disease. <em>Lancet</em>
1989;2:570.</li>

<li class="Ref">Yanase T, Fukahori M, Taniguchi S, et al. Serum dehydroepiandrosterone (DHEA)
and DHEA-sulfate (DHEA-S) in Alzheimer&#8217;s disease and in cerebrovascular dementia. <em>
Endocr J</em> 1996;43:119&#8211;23.</li>

<li class="Ref">Birkenhager-Gillesse EG, Derksen J, Lagaay AM. Dehydroepiandrosterone sulphate
(DHEAS) in the oldest old, aged 85 and over. <em>Ann N Y Acad Sci</em>
1994;719:543&#8211;52.</li>

<li class="Ref">Schneider LS, Hinsey M, Lyness S. Plasma dehydroepiandrosterone sulfate in
Alzheimer&#8217;s disease. <em>Biol Psychiatry</em> 1992;31:205&#8211;8.</li>

<li class="Ref">Wolkowitz OM, Kramer JH, Reus VI, et al. Dehydroepiandrosterone (NPI-34133)
treatment of Alzheimer&#8217;s disease: a randomized, double-blind, placebo-controlled,
parallel group study. Presented at the annual meeting of the American Psychiatric Association,
Washington, DC, May 15&#8211;20, 1999.</li>

<li class="Ref">Dukoff R, Molchan S, Putnam K, et al. Dehydroepiandrosterone administration in
demented patients and non-demented elderly volunteers. <em>Biol Psychiatry</em>
1999;46:1533&#8211;41.</li>

<li class="Ref">Le Bars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind,
randomized trial of an extract of <em>Ginkgo biloba</em> for dementia. North American EGb
Study Group. <em>JAMA</em> 1997;278:1327&#8211;32.</li>

<li class="Ref">Hofferberth B. The efficacy of EGb 761 in patients with senile dementia of the
Alzheimer type, a double-blind, placebo-controlled study on different levels of investigation.
<em>Hum Psychopharmacol</em> 1994;9:215&#8211;22.</li>

<li class="Ref">Kanowski S, Herrmann W, Stephan K, et al. Proof of efficacy of the <em>Ginkgo
biloba</em> special extract EGb 761 in outpatients suffering from mild to moderate primary
degenerative dementia of the Alzheimer type or multi-infarct dementia. <em>
Pharmacopsychiatry</em> 1996;29:47&#8211;56.</li>

<li class="Ref">Maurer K, Ihl R, Dierks T, Frolich L. Clinical efficacy of <em>Ginkgo
biloba</em> special extract EGb 761 in dementia of the Alzheimer&#8217;s type. <em>J Psychiatr
Res</em> 1997;31:645&#8211;55.</li>

<li class="Ref">van Dongen M, van Rossum E, Kessels A, et al. The efficacy of ginkgo for
elderly people with dementia and age-associated memory impairment: New results of a randomized
clinical trial. <em>J Am Geriatr Soc</em> 2000;48:1183&#8211;94.</li>

<li class="Ref">Wettstein A. Cholinesterase inhibitors and Ginkgo extracts&#8211;are they
comparable in the treatment of dementia? Comparison of published placebo-controlled efficacy
studies of at least six months&#8217; duration. <em>Phytomedicine</em>
2000;6:393&#8211;401.</li>

<li class="Ref">Xu SS, Gao ZX, Weng Z, et al. Efficacy of tablet huperzine-A on memory,
cognition, and behavior in Alzheimer&#8217;s disease. <em>Chung Kuo Yao Li Hsueh Pao</em>
1995;16:391&#8211;5.</li>

<li class="Ref">Zhang RW, Tang XC, Han YY, et al. Drug evaluation of huperzine A in the
treatment of senile memory disorders. <em>Chung Kuo Yao Li Hsueh Pao</em> 1991;12:250&#8211;2
[in Chinese].</li>

<li class="Ref">Wang Z, Ren G, Zhao Y, et al. A double-blind study of huperzine A and
piracetam in patients with age-associated memory impairment and dementia. In: Kanba S,
Richelson E, eds. <em>Herbal Medicines for Nonpsychiatric Diseases</em>. Tokyo: Seiwa Shoten
Publishers, 1999, 39&#8211;50.</li>

<li class="Ref">Thal LJ, Salmon DP, Lasker B, et al. The safety and lack of efficacy of
vinpocetine in Alzheimer&#8217;s disease. <em>J Am Geriatr Soc</em> 1989;37:515&#8211;20.</li>

<li class="Ref">Fischhof PK, Moslinger-Gehmayr R, Herrmann WM, et al. Therapeutic efficacy of
vincamine in dementia. <em>Neuropsychobiology</em> 1996;34:29&#8211;35.</li>
</ol>
</div>
</body>

<!-- Mirrored from www.naturesbounty.com/vf/healthnotes/HN_Live/Spanish/Es-Concern/Alzheimers.ref.htm by HTTrack Website Copier/3.x [XR&CO'2005], Thu, 03 Mar 2005 14:30:05 GMT -->
</html>

